Artificial intelligence-based tool could improve multiple myeloma treatment decisions
Artificial intelligence-based tool could improve multiple myeloma treatment decisions
Publish Date: 2026-05-21 22:39:00
Source Domain: www.news-medical.net
An artificial intelligence-based tool may help physicians determine which newly diagnosed multiple myeloma patients are most likely to benefit from specific therapies, including immunotherapy and stem cell transplantation.
Researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, found that immune-related signals hidden within routine bone marrow biopsy slides could predict differences in patient outcomes and support more personalized treatment strategies. The findings will be presented by Sylvester research scientist Arjun Raj Rajanna, at the 2026 American Society of Clinical Oncology (ASCO) annual meeting.
Doctors treating multiple myeloma have more treatment options than ever before, including powerful immunotherapies and expanded access to stem cell transplants. Yet deciding which patients need the most intensive therapies, and which may safely avoid them, remains a major challenge.
The new research shows that artificial intelligence can uncover clinically meaningful immune signals hidden in standard bone marrow biopsy slides. Those insights could help physicians tailor treatment strategies for patients newly diagnosed with multiple myeloma.
We are using AI to move toward a more precision-based treatment approach for patients with multiple myeloma. Instead of asking which drug combination is best overall, we are using AI to ask which treatment strategy best fits the biology of each individual patient.”
Arjun Raj Rajanna, Sylvester research scientist
Multiple myeloma is a blood cancer that develops in the bone marrow. Treatment options have expanded rapidly in recent years. One such therapy is daratumumab, a monoclonal antibody that helps the immune system’s natural killer cells recognize and attack myeloma cells.
Another common treatment is autologous stem cell transplantation. While this approach can extend the time before the cancer returns, it also carries significant side…
